The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks

Background: Life expectancy for patients with malignant tumors has been significantly improved since the presence of the programmed cell death protein-1/programmed cell death protein ligand-1 (PD-1/PD-L1) inhibitors in 2014, but they impose heavy financial burdens for patients, the healthcare system...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Shen, Huang, Yaping, Dong, Liangliang, Li, Meiyue, Wang, Yahong, Gu, Dian, Wu, Wei, Nian, Dongni, Luo, Shaohong, Huang, Xiaoting, Xu, Xiongwei, Weng, Xiuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995671/
https://www.ncbi.nlm.nih.gov/pubmed/36909180
http://dx.doi.org/10.3389/fphar.2023.1114304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995671/
https://www.ncbi.nlm.nih.gov/pubmed/36909180
http://dx.doi.org/10.3389/fphar.2023.1114304

Ejemplares similares